In The News

400 jobs coming to West Chester Twp. through $750M Resilience-Lilly expansion

July 31, 2026  |  Resilience
Resilience

Investment will expand production of Lilly's KwikPen device and bring Resilience's Ohio workforce to about 1,400.

 

A $750 million expansion by Resilience and Eli Lilly and Company is expected to create more than 400 new jobs in West Chester Twp., further growing the region's role in pharmaceutical manufacturing.

 

The investment will expand production of Lilly's KwikPen injectable device at Resilience's West Chester campus, increasing domestic manufacturing capacity for treatments used to manage diabetes and obesity.

 

Resilience is a contract development and manufacturing organization that produces medicines and drug delivery products for pharmaceutical companies. The company focuses on manufacturing complex therapies and expanding U.S.-based production capacity for critical medicines.

 

The project will bring Resilience's total Ohio workforce to about 1,400 employees. Site preparation is underway, and full operations are expected to begin in 2027.

 

 Measles outbreak reported in northeast Ohio; Third outbreak in the state this year

"Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the United States, and demonstrates how trusted partnerships, operational excellence and disciplined execution can strengthen America's medicine supply," said William S. Marth, president and chief executive officer of Resilience.

 

Lilly officials said the announcement builds on a partnership that began in 2023.

"Today's announcement highlights Resilience's role as a strong partner to Lilly in strengthening domestic supply of high-demand treatments," said Edgardo Hernandez, Lilly's executive vice president and president of manufacturing operations.

 

According to the companies, the partnership has already produced more than 150 million medicine doses for U.S. patients and helped establish one of the nation's largest sterile injectable manufacturing operations.

 

The expansion follows Resilience's decision in June to relocate its corporate headquarters from San Diego to Blue Ash. The headquarters at 10901 Kenwood Road serves as the center of the company's Ohio-based sterile injectable manufacturing and packaging network. Its West Chester facility is at 8848 Trade Port Drive.

Gov. Mike DeWine said the latest investment underscores Ohio's growing life sciences sector.

 

"Today's announcement further validates the state's life science workforce, infrastructure and collaborative approach to economic development," DeWine said.

 

Resilience purchased AstraZeneca's 580,000-square-foot facility in West Chester Twp. in November 2022 and has operated the site since then. Combined with another Ohio facility, the company's operations total nearly 1 million square feet.

 

The company has partnered with JobsOhio, REDI Cincinnati and Ohio Life Sciences to help develop a pipeline of skilled workers for the growing industry.

 

"Statewide investments in biomanufacturing training are preparing Ohioans for careers with Resilience and other industry leaders seeking growth," said JobsOhio President and CEO J.P. Nauseef.

 

https://www.journal-news.com/local/400-jobs-coming-to-west-chester-twp-through-750m-resilience-lilly-expansion/article_b7bfb2eb-2a77-5e17-84fa-37c428a22e81.html?fbclid=IwY2xjawTZfKNwZG9mBWV4dG4DYWVtAjExAHNydGMGYXBwX2lkEDIyMjAzOTE3ODgyMDA4OTIAAR4nJedeEwdbnQACjy33xdyBq9ExKXOFOizTz1ayZKaYkHog5vRlsnZ8YR0q1A_aem_AAcVQk-1xXN0WpDt9L4kwA